Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients

Experimental and Therapeutic Medicine

Volumn 3, Issue 3, 2012, Pages 391-396

  Luo, Deng ^a   Ye, Ting ^a   Li, Tian Qian ^a   Tang, Peng ^a   Min, Sha Dong ^a   Zhao, Gong Fang ^a   Huang, Hua ^a   Chang, Jiang ^a   Wang, Yan ^a   Lin, L V ^a   Lu, Ming Liang ^a   Zheng, Meng Yao ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Metastasis; Prognosis; RASSF2

Indexed keywords

PROTEIN RASSF2; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CHINESE; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH MUCOSA;

EID: 84862922521     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.440     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Ye YW, Dong RZ, Zhou Y, et al: Prognostic analysis of familial gastric cancer in Chinese population. J Surg Oncol 104: 76-82, 2011.
3. Thun M, Jemal A, Desantis C, et al: An overview of the cancer burden for primary care physicians. Prim Care 36: 439-454, 2009.
4. Chen JG, Zhu J, Zhang YH and Lu JH: Cancer survival in Qidong, China, 1992-2000. IARC Sci Publ: 43-53, 2011.
5. Law SC and Mang OW: Cancer survival in Hong Kong SAR, China, 1996-2001. IARC Sci Publ: 33-41, 2011.
6. Xiang YB, Jin F and Gao YT: Cancer survival in Shanghai, China, 1992-1995. IARC Sci Publ: 55-68, 2011.
7. Xishan H, Chen K, Min H, et al: Cancer survival in Tianjin, China, 1991-1999. IARC Sci Publ: 69-84, 2011.
8. Rodriguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339, 2011.
9. Watanabe Y and Maekawa M: Methylation of DNA in cancer. Adv Clin Chem 52: 145-167, 2010.
10. Hatziapostolou M and Iliopoulos D: Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68: 1681-1702, 2011.
11. Liu C, Pan Y, Wang X, et al: Activation of RASSF2A by p300 induces late apoptosis through histone hyperacetylation. Cell Biol Int 34: 1133-1139, 2010.
12. Akino K, Toyota M, Suzuki H, et al: The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129: 156-169, 2005.
13. Kaira K, Sunaga N, Tomizawa Y, et al: Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 31: 169-173, 2007.
14. Zhang Z, Sun D, Van do N, et al: Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 120: 32-38, 2007.
15. Cooper WN, Dickinson RE, Dallol A, et al: Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27: 1805-1811, 2008.
16. Imai T, Toyota M, Suzuki H, et al: Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 99: 958-966, 2008.
17. Kumari G, Singhal PK, Rao MR and Mahalingam S: Nuclear transport of Ras-associated tumor suppressor proteins: different transport receptor binding specificities for arginine-rich nuclear targeting signals. J Mol Biol 367: 1294-1311, 2007.
18. Song H, Oh S, Oh HJ and Lim DS: Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun 391: 969-973, 2010.
19. Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17: 3077-3079, 2010.
20. Santiago JM, Sasako M and Osorio J: TNM-7th edition 2009 (UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer. Towards simplicity and standardisation in the manage- ment of gastric cancer. Cir Esp 89: 275-281, 2011 (In Spanish).
21. Resende C, Ristimaki A and Machado JC: Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 15 (Suppl 1): 34-39, 2010.
22. Nobili S, Bruno L, Landini I, et al: Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 17: 290-299, 2011.
23. Donninger H, Hesson L, Vos M, et al: The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 30: 2608-2620, 2010.
24. Hesson LB, Wilson R, Morton D, et al: CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24: 3987-3994, 2005.
25. Endoh M, Tamura G, Honda T, et al: RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 93: 1395-1399, 2005.
26. Steinmann K, Sandner A, Schagdarsurengin U and DammannRH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 22: 1519-1526, 2009.
27. Ren J, He W, Zhang R, et al: RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level. JHuazhong Univ Sci Technolog Med Sci 29: 309-312, 2009.
28. Schagdarsurengin U, Richter AM, Hornung J, et al: Frequent epigenetic inactivation of RASSF2 in thyroid cancer and func- tional consequences. Mol Cancer 9: 264, 2010.
29. Maruyama R, Akino K, Toyota M, et al: Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29: 1312-1318, 2008.